In Vivo Efficacy of Matinas BioPharma’s Oral MAT2203 in Pulmonary Mucormycosis Published in Journal of Antimicrobial Agents and Chemotherapy

2 years ago

Studies in neutropenic mouse model demonstrate prolonged and enhanced survival, reduced fungal burden and improvement in lung infectionBEDMINSTER, N.J., April…

Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600

2 years ago

Dosing of all patients in the trial has been successfully completed Final results are expected to be available in late…

Shape Therapeutics to Showcase RNA Editing in the Brain and Validation of their Stable AAV Producer Cell Line at ASGCT 2024

2 years ago

SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Shape Therapeutics, a leader at the convergence of AI and RNA editing to…

Ultragenyx Announces Completion of Enrollment in Phase 3 Orbit and Cosmic Studies Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)

2 years ago

NOVATO, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that all patients have been…

Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024

2 years ago

NEW HOPE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”),…

Mobile-health Network Solutions Opens New Retail Pharmacy

2 years ago

SINGAPORE, April 30, 2024 (GLOBE NEWSWIRE) -- Mobile-health Network Solutions (Nasdaq: MNDR) (“MaNaDr” or “the Company”), a leading Asia-Pacific telehealth…

BioRestorative Therapies Announces Transformative Commercial Agreement with Cartessa, a Global Leader in Medical Aesthetics Technology

2 years ago

— Leading regenerative medicine and aesthetics innovators collaborate to build a vertically integrated, best-in-class biocosmeceutical platform — — Exclusive, five…

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

2 years ago

NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery,…

Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position

2 years ago

Improvements realized through comprehensive resource realignment ensuring robust investment in the commercial launch of PEMGARDATM and the discovery of novel…

XOMA Adds Economic Interests in Three First-in-Category Assets to its Royalty and Milestone Portfolio Including XACIATO™ (clindamycin phosphate) Vaginal Gel 2%

2 years ago

Organon, a global women’s healthcare company, initiated XACIATO™ commercial activities in the fourth quarter of 2023 XOMA further expands its…